DK1725253T3 - Medikamenter og fremgangsmåder til behandling af hovedpine - Google Patents

Medikamenter og fremgangsmåder til behandling af hovedpine

Info

Publication number
DK1725253T3
DK1725253T3 DK05723092.2T DK05723092T DK1725253T3 DK 1725253 T3 DK1725253 T3 DK 1725253T3 DK 05723092 T DK05723092 T DK 05723092T DK 1725253 T3 DK1725253 T3 DK 1725253T3
Authority
DK
Denmark
Prior art keywords
medications
methods
treating headaches
headaches
treating
Prior art date
Application number
DK05723092.2T
Other languages
English (en)
Inventor
Catherine C Turkel
Mitchell F Brin
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/789,180 external-priority patent/US9078892B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1725253T3 publication Critical patent/DK1725253T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
DK05723092.2T 2004-02-26 2005-02-15 Medikamenter og fremgangsmåder til behandling af hovedpine DK1725253T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/789,180 US9078892B2 (en) 2004-02-26 2004-02-26 Methods for treating pain and for treating a medication overuse disorder
US11/039,506 US20050191321A1 (en) 2004-02-26 2005-01-18 Methods for treating headache
PCT/US2005/004778 WO2005082339A2 (en) 2004-02-26 2005-02-15 Medicaments and methods for treating headache

Publications (1)

Publication Number Publication Date
DK1725253T3 true DK1725253T3 (da) 2014-07-07

Family

ID=34914767

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05723092.2T DK1725253T3 (da) 2004-02-26 2005-02-15 Medikamenter og fremgangsmåder til behandling af hovedpine

Country Status (17)

Country Link
US (10) US20050191321A1 (da)
EP (3) EP1725253B1 (da)
JP (1) JP4913721B2 (da)
KR (1) KR20060126793A (da)
CN (1) CN103251937B (da)
AU (2) AU2005216887A1 (da)
BR (1) BRPI0508231A (da)
CA (2) CA2982313A1 (da)
CY (1) CY1115104T1 (da)
DK (1) DK1725253T3 (da)
ES (1) ES2460731T3 (da)
HK (2) HK1098072A1 (da)
MX (1) MX337511B (da)
PL (1) PL1725253T3 (da)
PT (1) PT1725253E (da)
SI (1) SI1725253T1 (da)
WO (1) WO2005082339A2 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US7311666B2 (en) * 2004-07-10 2007-12-25 Trigeminal Solutions, Inc. Apparatus for collecting information
WO2006078588A2 (en) * 2005-01-18 2006-07-27 Allergan, Inc. Improved methods for treating headache
AU2012241076B2 (en) * 2005-02-01 2015-05-14 Allergan, Inc. Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080103546A1 (en) * 2006-10-27 2008-05-01 Cyberonics, Inc. Patient management system for treating epilepsy using an implantable medical device
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
CN103813802A (zh) 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US20130236446A1 (en) 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
AU2013232758C1 (en) 2012-03-12 2015-03-05 William J. Binder Treatment of migraine headaches with presynaptic neurotoxin
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2919807B1 (en) * 2012-11-16 2018-07-11 Finzi, Eric Treatment of post-traumatic stress disorder using botulinum toxin a
US20160045423A1 (en) 2013-03-22 2016-02-18 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9254314B2 (en) * 2013-11-12 2016-02-09 Eric Finzi Treatment of social anxiety disorder, obsessive compulsive disorder and panic disorder using botulinum toxin
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
WO2016149092A1 (en) 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
US10456419B2 (en) 2017-02-27 2019-10-29 Payman Sadeghi Method for treating migraine headaches
US10932711B2 (en) 2017-02-27 2021-03-02 Payman Sadeghi Method and system for neurohydrodissection
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
CA3068292A1 (en) * 2017-06-26 2019-01-03 Bonti, Inc. Clostridial neurotoxin formulations and use
CA3172150A1 (en) * 2020-03-18 2021-09-23 Revance Therapeutics, Inc. Injectable botulinum toxin methods for treating headaches

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69434610T2 (de) * 1993-12-28 2008-11-27 Allergan, Inc., Irvine Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3066079B2 (ja) * 1994-05-09 2000-07-17 ビンダー,ウィリアム,ジェイ. 頭痛を低減する方法
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5670181A (en) * 1995-10-20 1997-09-23 Stokes; Christine P. Apparatus and method for slip casting for ceramic objects
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
BR9914891A (pt) * 1998-10-27 2001-07-17 Mayo Foundation Processos para aperfeiçoamento de cura de ferimento
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP1586329A1 (en) * 2000-02-08 2005-10-19 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
KR100602308B1 (ko) 2001-07-27 2006-07-18 더 보드 오브 수퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 미케니칼 칼리지 여드름의 치료 또는 예방을 위한 보툴리눔 독소
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
US20030224019A1 (en) * 2002-03-01 2003-12-04 O'brien Christopher Methods of treating nerve entrapment syndromes
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
MXPA05009425A (es) * 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8609112B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) * 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US7655244B2 (en) * 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
TWI282083B (en) * 2005-05-27 2007-06-01 Innolux Display Corp Backlight on/off control circuit
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
WO2007025249A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
CA2823974A1 (en) * 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
US8940308B2 (en) * 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
CN103813802A (zh) * 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
US20130236446A1 (en) * 2012-03-12 2013-09-12 William J. Binder Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the mouth
CN104203202B (zh) * 2012-04-03 2018-04-06 巴斯夫欧洲公司 包含植物卵磷脂的发用化妆品组合物
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
AU2013377842B2 (en) * 2013-02-06 2017-07-27 Agilent Technologies, Inc. Fluidic coupling devices, assemblies, and related methods
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CA2947006A1 (en) * 2014-04-30 2015-11-05 Eric A. Forssen Formulations of biologics for intravesical instillation
EP3191118A1 (en) * 2014-09-12 2017-07-19 Allergan, Inc. Methods for treating osteoarthritis pain
WO2016149092A1 (en) * 2015-03-13 2016-09-22 Allergan, Inc. Improved injection paradigm for administration of botulinum toxins

Also Published As

Publication number Publication date
AU2005216887A1 (en) 2005-09-09
CN103251937A (zh) 2013-08-21
US20060104995A1 (en) 2006-05-18
HK1098072A1 (en) 2007-07-13
SI1725253T1 (sl) 2014-05-30
US20100189655A1 (en) 2010-07-29
JP2007525505A (ja) 2007-09-06
US20090263426A1 (en) 2009-10-22
KR20060126793A (ko) 2006-12-08
AU2011201107B2 (en) 2012-12-20
EP2433643A1 (en) 2012-03-28
EP1725253B1 (en) 2014-04-09
US9555085B2 (en) 2017-01-31
WO2005082339A2 (en) 2005-09-09
CY1115104T1 (el) 2016-12-14
AU2011201107A1 (en) 2011-04-07
US20170128552A1 (en) 2017-05-11
ES2460731T3 (es) 2014-05-14
US20150313974A1 (en) 2015-11-05
CA2982313A1 (en) 2005-09-09
WO2005082339A3 (en) 2005-12-01
CA2557588A1 (en) 2005-09-09
PL1725253T3 (pl) 2014-08-29
EP2752197A1 (en) 2014-07-09
US8889151B2 (en) 2014-11-18
EP1725253A2 (en) 2006-11-29
US20220088157A1 (en) 2022-03-24
CN103251937B (zh) 2015-10-07
US7704511B2 (en) 2010-04-27
JP4913721B2 (ja) 2012-04-11
CA2557588C (en) 2017-11-28
US9078893B2 (en) 2015-07-14
US10092631B2 (en) 2018-10-09
US20050191321A1 (en) 2005-09-01
HK1199403A1 (en) 2015-07-03
PT1725253E (pt) 2014-05-06
US20200230217A1 (en) 2020-07-23
EP2752197B1 (en) 2019-11-20
EP2433643B1 (en) 2015-12-02
BRPI0508231A (pt) 2007-07-17
US10603366B2 (en) 2020-03-31
US20190038726A1 (en) 2019-02-07
MX337511B (es) 2016-03-09
US20060121057A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
DK1725253T3 (da) Medikamenter og fremgangsmåder til behandling af hovedpine
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
IS8204A (is) Tæki og aðferð til að hluta niður
DK2878297T3 (da) Lægemidler til behandling og forebyggelse af fibrotiske sygdomme
DK1948852T3 (da) Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden
DK1620182T3 (da) Metoder til behandling af bihule-hovedpine
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK1997291T3 (da) Metode og anordning til sikker godkendelse
DK1759318T3 (da) Fremgangsmåder og systemer til at administrere data
NO20051106D0 (no) System og fremgangsmate ved bronnboring
DK1791791T3 (da) Fremgangsmåder og sammensætninger til behandling af vand
DK1909965T3 (da) Fremgangsmåde og indretning til manipulation af partikler
DE602006017285D1 (de) Kryptographisches Kommunikationssystem und -methode
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
DK1929123T3 (da) Fremgangsmåde og anordning i tilknytning til stimulationsbehandlinger af borehuller
EP1755733A4 (en) METHOD AND DEVICES FOR THERMAL TREATMENT
DE602005005527D1 (de) Verschlussdüse
DE602005001520D1 (de) Zeiteinstellungssystem und Zeiteinstellungsverfahren
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
HK1089883A1 (en) Authentication method and devices
DE602005019525D1 (de) Verschlussdüse
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer
DK1864987T3 (da) Fremgangsmåder til fremstilling af 3-O-beskyttede morphinoner og 3-O-beskyttede morphinon-dienol-carboxylater
NO20043002L (no) Anordning og fremgangsmate til diskontinuerlig polykondensasjon
DK1768691T3 (da) Aequorinholdige præparater og fremgangsmåder til anvendelse af samme